SCHEMBL25400534

SCHEMBL25400534

CCN(CC)c1ccc(C(=O)c2cc(Br)c3cc(C(C)=O)ccn23)cc1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MAPT P10636 9/20 0.43
▸ MEN1 O00255 3/20 0.43
▸ KMT2A Q03164 3/20 0.43
▸ POLB P06746 3/20 0.43
▸ MCL1 Q07820 2/20 0.43
▸ NOX1 Q9Y5S8 2/20 0.43
▸ GAA P10253 2/20 0.43
▸ ALDH1A1 P00352 9/20 0.42
▸ MAPK1 P28482 4/20 0.42
▸ TSHR P16473 4/20 0.42
▸ USP2 O75604 2/20 0.42
▸ TP53 P04637 1/20 0.42
▸ PKM P14618 1/20 0.42
▸ NPC1 O15118 3/20 0.38
▸ RAB9A P51151 3/20 0.38
▸ L3MBTL1 Q9Y468 2/20 0.38
▸ CRHR1 P34998 2/20 0.37
▸ HTT P42858 2/20 0.37
▸ SMN1; SMN2 Q16637 2/20 0.37
▸ LMNA P02545 2/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL26304348 0.85 MAPT (0.45) MAPTMEN1KMT2APOLBMCL1
SCHEMBL29547228 0.83 FNTA (0.51) MAPTMEN1KMT2APOLBNOX1
SCHEMBL29547156 0.83 L3MBTL1 (0.36) MAPTMEN1KMT2APOLBMCL1
SCHEMBL26301287 0.82 BAZ2B (0.52) MAPTMEN1KMT2APOLBMCL1
SCHEMBL25401220 0.81 FNTA (0.51) MAPTMEN1KMT2AALDH1A1L3MBTL1
SCHEMBL26301762 0.81 BAZ2B (0.47) MAPTMEN1KMT2APOLBMCL1
SCHEMBL26301245 0.80 SMARCA2 (0.41) MAPTMEN1KMT2APOLBMCL1
SCHEMBL25402588 0.80 LMNA (0.46) MAPTMEN1KMT2AGAAALDH1A1
SCHEMBL26304344 0.79 BAZ2B (0.39) MAPTMEN1KMT2APOLBMCL1
SCHEMBL29547188 0.79 ALDH1A1 (0.40) MAPTALDH1A1NPC1RAB9AFNTA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4233864-B1 COMPOSITION COMPRISING AN INDOLIZINE DERIVATIVE AND A CYCLIC DINUCLEOTIDE AS ACTIVE AGENTS UNIV AJOU IND ACADEMIC COOP FOUND (KR) 2025-02-12 — — EP disclosed
US-20230390319-A1 INTERFERON GENE STIMULATOR COMPOSITION COMPRISING INDOLIZINE DERIVATIVE AS ACTIVE INGREDIENT KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY (KR) 2023-12-07 — — US disclosed
EP-4233864-A1 INTERFERON GENE STIMULATOR COMPOSITION COMPRISING INDOLIZINE DERIVATIVE AS ACTIVE INGREDIENT Ajou University Industry-Academic Cooperation Foundation (KR) 2023-08-30 — — EP disclosed
WO-2022086260-A1 INTERFERON GENE STIMULATOR COMPOSITION COMPRISING INDOLIZINE DERIVATIVE AS ACTIVE INGREDIENT 아주대학교산학협력단 2022-04-28 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230390319-A1 INTERFERON GENE STIMULATOR COMPOSITION COMPRISING INDOLIZINE DERIVATIVE AS ACTIVE INGREDIENT STING1, IRF3, IFNG MAPT 4769/4885MEN1 2319/4885KMT2A 4595/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback